Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Peptide CDMO
1.2.3 Oligonucleotide CDMO
1.3 Market by Application
1.3.1 Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide and Oligonucleotide CDMO Market Perspective (2018-2033)
2.2 Global Peptide and Oligonucleotide CDMO Growth Trends by Region
2.2.1 Peptide and Oligonucleotide CDMO Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Peptide and Oligonucleotide CDMO Historic Market Size by Region (2018-2023)
2.2.3 Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2024-2033)
2.3 Peptide and Oligonucleotide CDMO Market Dynamics
2.3.1 Peptide and Oligonucleotide CDMO Industry Trends
2.3.2 Peptide and Oligonucleotide CDMO Market Drivers
2.3.3 Peptide and Oligonucleotide CDMO Market Challenges
2.3.4 Peptide and Oligonucleotide CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Peptide and Oligonucleotide CDMO by Players
3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Peptide and Oligonucleotide CDMO, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio
3.4.1 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide and Oligonucleotide CDMO Revenue in 2022
3.5 Global Key Players of Peptide and Oligonucleotide CDMO Head office and Area Served
3.6 Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application
3.7 Global Key Players of Peptide and Oligonucleotide CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide and Oligonucleotide CDMO Breakdown Data by Type
4.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Type (2018-2023)
4.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2024-2033)
5 Peptide and Oligonucleotide CDMO Breakdown Data by Application
5.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Application (2018-2023)
5.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Peptide and Oligonucleotide CDMO Market Size (2018-2033)
6.2 North America Peptide and Oligonucleotide CDMO Market Size by Type
6.2.1 North America Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
6.2.2 North America Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
6.2.3 North America Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
6.3 North America Peptide and Oligonucleotide CDMO Market Size by Application
6.3.1 North America Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.3.2 North America Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
6.3.3 North America Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
6.4 North America Peptide and Oligonucleotide CDMO Market Size by Country
6.4.1 North America Peptide and Oligonucleotide CDMO Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
6.4.3 North America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO Market Size (2018-2033)
7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type
7.2.1 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
7.2.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
7.2.3 Europe Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application
7.3.1 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
7.3.2 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
7.3.3 Europe Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
7.4 Europe Peptide and Oligonucleotide CDMO Market Size by Country
7.4.1 Europe Peptide and Oligonucleotide CDMO Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
7.4.3 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Peptide and Oligonucleotide CDMO Market Size (2018-2033)
8.2 China Peptide and Oligonucleotide CDMO Market Size by Type
8.2.1 China Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
8.2.2 China Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
8.2.3 China Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
8.3 China Peptide and Oligonucleotide CDMO Market Size by Application
8.3.1 China Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
8.3.2 China Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
8.3.3 China Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Peptide and Oligonucleotide CDMO Market Size (2018-2033)
9.2 Asia Peptide and Oligonucleotide CDMO Market Size by Type
9.2.1 Asia Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
9.2.2 Asia Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
9.2.3 Asia Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
9.3 Asia Peptide and Oligonucleotide CDMO Market Size by Application
9.3.1 Asia Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
9.3.2 Asia Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
9.3.3 Asia Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
9.4 Asia Peptide and Oligonucleotide CDMO Market Size by Region
9.4.1 Asia Peptide and Oligonucleotide CDMO Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023)
9.4.3 Asia Peptide and Oligonucleotide CDMO Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Type
10.2.1 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Application
10.3.1 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Country
10.4.1 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Details
11.1.2 Lonza Group Ltd. Business Overview
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Introduction
11.1.4 Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.1.5 Lonza Group Ltd. Recent Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Details
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Introduction
11.2.4 Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.2.5 Thermo Fisher Scientific Inc. Recent Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Details
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Introduction
11.3.4 Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.3.5 Merck KGaA Recent Developments
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Details
11.4.2 Catalent, Inc. Business Overview
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Introduction
11.4.4 Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.4.5 Catalent, Inc. Recent Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Details
11.5.2 Genscript Biotech Corporation Business Overview
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Introduction
11.5.4 Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.5.5 Genscript Biotech Corporation Recent Developments
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Details
11.6.2 Polypeptide Group Business Overview
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Introduction
11.6.4 Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.6.5 Polypeptide Group Recent Developments
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Details
11.7.2 Bachem Holding AG Business Overview
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Introduction
11.7.4 Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.7.5 Bachem Holding AG Recent Developments
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Details
11.8.2 Wuxi Apptec Co., Ltd. Business Overview
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Introduction
11.8.4 Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.8.5 Wuxi Apptec Co., Ltd. Recent Developments
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Details
11.9.2 Ajinomoto Co., Inc. Business Overview
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Introduction
11.9.4 Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.9.5 Ajinomoto Co., Inc. Recent Developments
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Details
11.10.2 Rentschler Biopharma SE Business Overview
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Introduction
11.10.4 Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.10.5 Rentschler Biopharma SE Recent Developments
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Details
11.11.2 Corden Pharma GmbH Business Overview
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Introduction
11.11.4 Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.11.5 Corden Pharma GmbH Recent Developments
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Details
11.12.2 Senn Chemicals AG Business Overview
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Introduction
11.12.4 Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.12.5 Senn Chemicals AG Recent Developments
11.13 Almac Group
11.13.1 Almac Group Company Details
11.13.2 Almac Group Business Overview
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Introduction
11.13.4 Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.13.5 Almac Group Recent Developments
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Details
11.14.2 Lonza Custom Manufacturing Business Overview
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Introduction
11.14.4 Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.14.5 Lonza Custom Manufacturing Recent Developments
11.15 Creative Peptides
11.15.1 Creative Peptides Company Details
11.15.2 Creative Peptides Business Overview
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Introduction
11.15.4 Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.15.5 Creative Peptides Recent Developments
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Details
11.16.2 Swiss Customized Synthesis Business Overview
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Introduction
11.16.4 Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.16.5 Swiss Customized Synthesis Recent Developments
11.17 Syngene
11.17.1 Syngene Company Details
11.17.2 Syngene Business Overview
11.17.3 Syngene Peptide and Oligonucleotide CDMO Introduction
11.17.4 Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.17.5 Syngene Recent Developments
11.18 Eurogentec
11.18.1 Eurogentec Company Details
11.18.2 Eurogentec Business Overview
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Introduction
11.18.4 Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.18.5 Eurogentec Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Peptide CDMO
Table 3. Key Players of Oligonucleotide CDMO
Table 4. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 5. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Peptide and Oligonucleotide CDMO Market Share by Region (2018-2023)
Table 8. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Peptide and Oligonucleotide CDMO Market Share by Region (2024-2033)
Table 10. Peptide and Oligonucleotide CDMO Market Trends
Table 11. Peptide and Oligonucleotide CDMO Market Drivers
Table 12. Peptide and Oligonucleotide CDMO Market Challenges
Table 13. Peptide and Oligonucleotide CDMO Market Restraints
Table 14. Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Peptide and Oligonucleotide CDMO Revenue Share by Players (2018-2023)
Table 16. Global Top Peptide and Oligonucleotide CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2022)
Table 17. Global Peptide and Oligonucleotide CDMO Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Peptide and Oligonucleotide CDMO Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Peptide and Oligonucleotide CDMO, Headquarters and Area Served
Table 20. Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application
Table 21. Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2018-2023)
Table 25. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2024-2033)
Table 27. Global Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Peptide and Oligonucleotide CDMO Revenue Share by Application (2018-2023)
Table 29. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Peptide and Oligonucleotide CDMO Revenue Share by Application (2024-2033)
Table 31. North America Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 33. North America Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 35. North America Peptide and Oligonucleotide CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. North America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 38. Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 40. Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 42. Europe Peptide and Oligonucleotide CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 45. China Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 47. China Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 49. Asia Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 51. Asia Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 53. Asia Peptide and Oligonucleotide CDMO Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 54. Asia Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Peptide and Oligonucleotide CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 61. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 63. Lonza Group Ltd. Company Details
Table 64. Lonza Group Ltd. Business Overview
Table 65. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product
Table 66. Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 67. Lonza Group Ltd. Recent Developments
Table 68. Thermo Fisher Scientific Inc. Company Details
Table 69. Thermo Fisher Scientific Inc. Business Overview
Table 70. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product
Table 71. Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 72. Thermo Fisher Scientific Inc. Recent Developments
Table 73. Merck KGaA Company Details
Table 74. Merck KGaA Business Overview
Table 75. Merck KGaA Peptide and Oligonucleotide CDMO Product
Table 76. Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 77. Merck KGaA Recent Developments
Table 78. Catalent, Inc. Company Details
Table 79. Catalent, Inc. Business Overview
Table 80. Catalent, Inc. Peptide and Oligonucleotide CDMO Product
Table 81. Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 82. Catalent, Inc. Recent Developments
Table 83. Genscript Biotech Corporation Company Details
Table 84. Genscript Biotech Corporation Business Overview
Table 85. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product
Table 86. Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 87. Genscript Biotech Corporation Recent Developments
Table 88. Polypeptide Group Company Details
Table 89. Polypeptide Group Business Overview
Table 90. Polypeptide Group Peptide and Oligonucleotide CDMO Product
Table 91. Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 92. Polypeptide Group Recent Developments
Table 93. Bachem Holding AG Company Details
Table 94. Bachem Holding AG Business Overview
Table 95. Bachem Holding AG Peptide and Oligonucleotide CDMO Product
Table 96. Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 97. Bachem Holding AG Recent Developments
Table 98. Wuxi Apptec Co., Ltd. Company Details
Table 99. Wuxi Apptec Co., Ltd. Business Overview
Table 100. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product
Table 101. Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 102. Wuxi Apptec Co., Ltd. Recent Developments
Table 103. Ajinomoto Co., Inc. Company Details
Table 104. Ajinomoto Co., Inc. Business Overview
Table 105. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product
Table 106. Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 107. Ajinomoto Co., Inc. Recent Developments
Table 108. Rentschler Biopharma SE Company Details
Table 109. Rentschler Biopharma SE Business Overview
Table 110. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product
Table 111. Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 112. Rentschler Biopharma SE Recent Developments
Table 113. Corden Pharma GmbH Company Details
Table 114. Corden Pharma GmbH Business Overview
Table 115. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product
Table 116. Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 117. Corden Pharma GmbH Recent Developments
Table 118. Senn Chemicals AG Company Details
Table 119. Senn Chemicals AG Business Overview
Table 120. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product
Table 121. Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 122. Senn Chemicals AG Recent Developments
Table 123. Almac Group Company Details
Table 124. Almac Group Business Overview
Table 125. Almac Group Peptide and Oligonucleotide CDMO Product
Table 126. Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 127. Almac Group Recent Developments
Table 128. Lonza Custom Manufacturing Company Details
Table 129. Lonza Custom Manufacturing Business Overview
Table 130. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product
Table 131. Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 132. Lonza Custom Manufacturing Recent Developments
Table 133. Creative Peptides Company Details
Table 134. Creative Peptides Business Overview
Table 135. Creative Peptides Peptide and Oligonucleotide CDMO Product
Table 136. Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 137. Creative Peptides Recent Developments
Table 138. Swiss Customized Synthesis Company Details
Table 139. Swiss Customized Synthesis Business Overview
Table 140. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product
Table 141. Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 142. Swiss Customized Synthesis Recent Developments
Table 143. Syngene Company Details
Table 144. Syngene Business Overview
Table 145. Syngene Peptide and Oligonucleotide CDMO Product
Table 146. Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 147. Syngene Recent Developments
Table 148. Eurogentec Company Details
Table 149. Eurogentec Business Overview
Table 150. Eurogentec Peptide and Oligonucleotide CDMO Product
Table 151. Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 152. Eurogentec Recent Developments
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Peptide and Oligonucleotide CDMO Market Share by Type: 2022 VS 2033
Figure 3. Peptide CDMO Features
Figure 4. Oligonucleotide CDMO Features
Figure 5. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 6. Global Peptide and Oligonucleotide CDMO Market Share by Application: 2022 VS 2033
Figure 7. Pharmaceutical and Biotechnology Companies Case Studies
Figure 8. Research Institutes Case Studies
Figure 9. Others Case Studies
Figure 10. Peptide and Oligonucleotide CDMO Report Years Considered
Figure 11. Global Peptide and Oligonucleotide CDMO Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Peptide and Oligonucleotide CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Peptide and Oligonucleotide CDMO Market Share by Region: 2022 VS 2033
Figure 14. Global Peptide and Oligonucleotide CDMO Market Share by Players in 2022
Figure 15. Global Top Peptide and Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Peptide and Oligonucleotide CDMO Revenue in 2022
Figure 17. North America Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 19. North America Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 20. North America Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 21. United States Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Peptide and Oligonucleotide CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 24. Europe Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 25. Europe Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 26. Europe Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 27. Germany Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. France Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. U.K. Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Italy Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Russia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Nordic Countries Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. China Peptide and Oligonucleotide CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 34. China Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 35. China Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 36. Asia Peptide and Oligonucleotide CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 37. Asia Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 38. Asia Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 39. Asia Peptide and Oligonucleotide CDMO Market Share by Region (2018-2033)
Figure 40. Japan Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. South Korea Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. China Taiwan Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Southeast Asia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. India Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Australia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Share by Type (2018-2033)
Figure 48. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Share by Application (2018-2033)
Figure 49. Middle East, Africa, and Latin America Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 50. Brazil Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 51. Mexico Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. Turkey Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Saudi Arabia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Israel Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. GCC Countries Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Lonza Group Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 57. Thermo Fisher Scientific Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 58. Merck KGaA Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 59. Catalent, Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 60. Genscript Biotech Corporation Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 61. Polypeptide Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 62. Bachem Holding AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 63. Wuxi Apptec Co., Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 64. Ajinomoto Co., Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 65. Rentschler Biopharma SE Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 66. Corden Pharma GmbH Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 67. Senn Chemicals AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 68. Almac Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 69. Lonza Custom Manufacturing Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 70. Creative Peptides Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 71. Swiss Customized Synthesis Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 72. Syngene Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 73. Eurogentec Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed